See what questions
a doctor would ask.
Cerivastatin, a cholesterol lowering statin, was pulled from the market several years ago due to the risk of rhabdomyolysis. Rhabdomyolysis can lead to kidney failure and ultimately death. Studies were then done on other statins such as atorvastatin, pravastatin and simvastatin which have all proven to have a similar risk of rhabdomyolysis as cervastatin. This risk is low but still present. One in 23,000 people who use the above statins are at risk with older diabetics who take a combination of fibrates and statins facing the greatest risk (1 in 500 annually). Cerivastatin combined with fibrates caused a dramatic increase in risk compared to the other statins (1 in 10 annually) thus justifying its removal and the safety of the other three.
Source: summary of medical news story as reported by News 8 Austin
About: Assessment of rhabdomyolysis risk of various cholesterol drugs
Date: 30 November 2004
Source: News 8 Austin
http:/ This summary article refers to the following medical categories:
Related Medical Topics
More News Topics
This summary article refers to the following medical categories:
Search Specialists by State and City